Cogent Biosciences (COGT) UBS Global Biopharma Conference 2026 summary
Event summary combining transcript, slides, and related documents.
UBS Global Biopharma Conference 2026 summary
17 Nov, 2026Regulatory milestones
Bezuclastinib, a selective KIT mutant inhibitor, completed pivotal studies in imatinib-resistant GIST and advanced and non-advanced systemic mastocytosis; positive readouts came in 2025–2026.
PDUFA dates: Nov. 30, 2026 for second-line GIST; Dec. 30, 2026 for non-advanced systemic mastocytosis; June 29, 2027 for advanced systemic mastocytosis.
GIST safety and market opportunity
Safety database exceeds 1,000 bezuclastinib-treated people; reported effects include taste changes, white hair growth and transaminase fluctuations, generally without clinical sequelae or need for dose changes.
Higher-grade transaminase elevations occurred early; monthly monitoring, as used with sunitinib, was cited as a proxy, with duration guided by clinical need.
Management expects any black-box warning or liver monitoring to have no noticeable impact on GIST uptake; it cited sunitinib’s existing warning and monitoring as established practice.
Estimated 2,500–3,000 patients annually become eligible after imatinib resistance; PEAK Phase III mean treatment duration was 21.4 months at the last check.
Modeled U.S. opportunity is $2.5B, with potential in Europe, Japan and other markets; rare cancer drug benchmarks cited were ~$44,000–$47,000+ monthly WAC.
Non-advanced systemic mastocytosis
Management described bezuclastinib as selective for KIT and non-CNS-penetrant, enabling clinically relevant dosing; it contrasted this with Ayvakit’s broader kinase activity, CNS penetration and 25 mg non-advanced dose.
Management cited improvements in serum tryptase, mast-cell burden and variant allele frequency, and reported undetectable bone-marrow mutant mast cells in nearly two-thirds of patients at six months.
Symptom scores use different trial scales; management said symptom improvement continued beyond six months and aims to emphasize clearance of disease-driving cells after launch.
Switch Study results in patients moving from avapritinib to bezuclastinib were expected at ASH in the coming weeks, with the study designed to assess symptom outcomes after switching.
Launch focus will include patients dissatisfied with or previously off Ayvakit; management expects hematologists to manage monitoring and treatment, with physician experience and patient advocacy supporting adoption.
Latest events from Cogent Biosciences
- Bezuclastinib nears U.S. decisions with launch readiness and pipeline expansion underway.COGT
3rd Annual Guggenheim Healthcare Innovation Conference - Three bezuclastinib FDA decisions loom as $791.1M in liquidity supports launch preparations.COGT
Q3 2026 - Three NDAs pending FDA review, strong trial results, and cash runway into late 2028.COGT
Q2 2026 - Pivotal trial readouts for bezuclastinib in rare diseases and GIST expected in 2025.COGT
Guggenheim SMID Cap Biotech Conference - All proposals, including director elections and auditor ratification, were approved.COGT
AGM 2026 - Bezuclastinib plus sunitinib delivers breakthrough efficacy in GIST, with rapid adoption anticipated.COGT
Jefferies Global Healthcare Conference 2026 - Bezuclastinib's pivotal trial wins set up a transformative 2026 launch and long-term market leadership.COGT
44th Annual J.P. Morgan Healthcare Conference - Bezuclastinib delivered robust symptom and biomarker improvements with good tolerability in non-advanced SM.COGT
Study Result - Pivotal trial readouts for Bezuclastinib in SM and GIST expected in 2025, with strong market potential.COGT
Piper Sandler 36th Annual Healthcare Conference